Reuters | May 06, 2020 06:30
(Reuters) - German healthcare group Fresenius (DE:FREG) beat first-quarter net income expectations on Wednesday, citing a spike in demand for drugs and devices for COVID-19 patients in Europe and the United States and German legislation to ease the financial burden on hospitals.
Fresenius' first-quarter net income came in at 465 million euros ($503.97 million), above analysts' average forecast of 421.8 million euros, according to a Refinitiv poll.
The group said it would revisit its 2020 guidance when publishing its second quarter results, when it could more reliably assess the impact of the pandemic.
Excluding that impact, Fresenius maintained its earlier 2020 outlook for net income growth of between 1% and 5% from a sales growth between 4% and 7% in constant currency terms.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Get free real time quotes, charts and alerts on stocks, indices, currencies, commodities and bonds. Get free top of the line technical analysis/predictors.
More content, faster quotes and charts, and a smoother experience is available only on the App.